Non-Exclusive Drug Discount Agreement for Etanercept
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Etanercept (ATC-Code nach WHO: L04AB01)
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
40 / 100
Risk factors
The buyer may terminate the open-house procedure early upon signing exclusive agreements, which historically occur 8–12...
No minimum purchase quantities; actual demand depends on patient numbers, prescribing habits, and pharmacy behavior.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Nov 30, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Nov 2026
- Conclusion of non-exclusive discount agreements for Etanercept
- Open-house model allowing all interested pharmaceutical entrepreneurs to participate
Show full summary
Non-exclusive pharmaceutical discount agreement for the active substance Etanercept (ATC L04AB01) under §130a(8) SGB V via an open-house model. The contract is open to all interested pharmaceutical entrepreneurs meeting the conditions, with no exclusivity and no guaranteed purchase volumes. The agreement runs until 30 November 2026.
Risks
The buyer may terminate the open-house procedure early upon signing exclusive agreements, which historically occur 8–12...
No minimum purchase quantities; actual demand depends on patient numbers, prescribing habits, and pharmacy behavior.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Pharmaceutical entrepreneur as per §4(18) AMG with EU/EEA establishment
- Compliance with EU Russia sanctions (Art. 5k Regulation 2022/576)
Eligibility
- No exclusion grounds under §§123, 124 GWB
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-Exclusive Drug Discount Agreement for Etanercept
Conclusion of non-exclusive discount agreements for Etanercept under §130a(8) SGB V via open-house model. No guaranteed quantities. Contract end: 30.11.2026.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Etanercept (ATC-Code nach WHO: L04AB01)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 19 Jan 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 38838-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
40 / 100
Risk factors
The buyer may terminate the open-house procedure early upon signing exclusive agreements, which historically occur 8–12...
No minimum purchase quantities; actual demand depends on patient numbers, prescribing habits, and pharmacy behavior.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications